New Study Offers First Evidence Of Vaping's Long-Term Risks
The study finds that e-cigarettes are linked to increased risk of chronic lung diseases including emphysema, chronic bronchitis and COPD, as well as weakened immune defenses. (Source: NPR Health and Science)
Source: NPR Health and Science - December 16, 2019 Category: Consumer Health News Authors: Allison Aubrey Source Type: news
Vaping Linked With Long-Term Risk Of Respiratory Disease In New Study
(CNN) — Vaping or using e-cigarettes for a long period of time was associated with an increased risk of respiratory diseases — including chronic obstructive pulmonary disease or COPD, chronic bronchitis and asthma — in a new study.
The study, published in the American Journal of Preventive Medicine on Monday, is among the first bodies of research to examine the link between e-cigarette use and respiratory disease in the long-term, by analyzing e-cigarette use and respiratory disease during a three-year period.
“I was a little surprised that we could find evidence on incident lung disease in the long...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 16, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Vaping Source Type: news
Vaping Damages Your Lungs, But Is Still Safer Than Smoking, a Long-Term Study Suggests
This study actually does support the harm reduction potential of e-cigarettes,” says Andy Tan, an assistant professor of population sciences at Dana-Farber Cancer Institute who has studied e-cigarettes. “Yes, vaping is associated with about 29% to 31% higher odds of subsequent lung disease within two to three years than not vaping—but compare this with the 156% higher odds of using combustible tobacco than not smoking.”
For the purposes of the study, Glantz and his co-author combined four conditions—chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema and asthma—in...
Source: TIME: Health - December 16, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized E-Cigarettes embargoed study Lung Disease Research vaping Source Type: news
Vaping Could Up Risks for Asthma, COPD and Other Lung Diseases
MONDAY, Dec. 16, 2019 -- As if the news on vaping wasn ' t bad enough, a new study suggests that e-cigarette users are also at significantly higher risk of chronic lung diseases such as asthma, bronchitis, emphysema and COPD.
Those risks rose even... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news
Medical News Today: Signs and symptoms of bronchitis
Bronchitis causes inflammation of the airways within the lungs. Find out about the symptoms of bronchitis, how it develops, and the treatment options available. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 9, 2019 Category: Consumer Health News Tags: Respiratory Source Type: news
Medical News Today: How long does bronchitis take to go away?
Bronchitis is an inflammatory condition affecting the lungs. Here we look at the differences between acute and chronic bronchitis, how long each type may last, and when to see a doctor for treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 22, 2019 Category: Consumer Health News Tags: Pulmonary System Source Type: news
Swiftly Ending Tobacco Epidemic Requires Government Action, Not Empty Promises
By Mark HurleyWASHINGTON DC, Oct 23 2019 (IPS) New information published in the Morbidity and Mortality Weekly Report shows that action taken by just 11 countries – most of them low- or middle-income – has resulted in 20 million fewer adult tobacco users in 2017 compared with 2008. Seventy percent of the world’s tobacco users live in low- and middle-income countries.
This promising progress is a testament to strong government action and its effects are far reaching. Between 2008 and 2017, over 53 million fewer adults were exposed to secondhand smoke in indoor public places like restaurants, government buildings and ...
Source: IPS Inter Press Service - Health - October 23, 2019 Category: International Medicine & Public Health Authors: Mark Hurley Tags: Development & Aid Editors' Choice Featured Global Global Governance Headlines Health Inequity IPS UN: Inside the Glasshouse Poverty & SDGs TerraViva United Nations Source Type: news
In a First, FDA Endorses Brand of Tobacco Pouches as a ‘Reduced Risk’ Alternative to Cigarettes
(WASHINGTON) — For the first time, U.S. health regulators have endorsed a brand of tobacco pouches as less harmful than cigarettes, a decision that could open the door to other less risky options for smokers.
The milestone announcement on Tuesday from the Food and Drug Administration marks the government’s first backing of a so-called “reduced risk” tobacco product.
FDA regulators stressed, though, that the Swedish Match pouches are not safe, just less harmful, and that all tobacco products pose risks. The pouches will still bear mandatory government warnings that they can cause mouth cancer, gum di...
Source: TIME: Health - October 22, 2019 Category: Consumer Health News Authors: MATTHEW PERRONE / AP Tags: Uncategorized FDA onetime Smoking Source Type: news
Minimally Invasive System Aims to Relieve Symptoms for Patients with Chronic Bronchitis
“Imagine somebody that gets bronchitis every day, with a cough so severe that they can’t talk in full sentences, they can’t sleep at night, and they can’t walk a decent distance,†said Jon Waldstreicher, MD, CEO of Gala Therapeutics, in an interview with MD+DI. Although someone with this condition might present to physicians with normal lung function, their chronic cough and mucous production negatively affects their quality of life.
Until now, there has been no way to treat these debilitating symptoms effectively, even with medicatio...
Source: MDDI - October 9, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Design Source Type: news
New Clinical Results from RheOx(TM) System for Chronic Bronchitis to be Presented at European Respiratory Society (ERS) International Congress
MENLO PARK, Calif., Sept. 26, 2019 -- (Healthcare Sales & Marketing Network) -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that clinical results and a patient case involving its RheOxTM Bronc... Devices Gala Therapeutics, RheOx system, Bronchial Rheoplasty, Chronic Bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 26, 2019 Category: Pharmaceuticals Source Type: news
Health Tip: Preventing Bronchitis
(Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 23, 2019 Category: Respiratory Medicine Tags: Pulmonology, FYI, Source Type: news
Health Tip: Preventing Bronchitis
-- Bronchitis is an inflammation of the bronchial tube lining, says Mayo Clinic. People who have bronchitis often cough up thick, discolored mucus. Though complications are rare, bronchitis can lead to pneumonia in some people.
To help prevent... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 23, 2019 Category: General Medicine Source Type: news
Health Tip: Preventing Bronchitis
Title: Health Tip: Preventing BronchitisCategory: Health NewsCreated: 9/23/2019 12:00:00 AMLast Editorial Review: 9/23/2019 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - September 23, 2019 Category: Respiratory Medicine Source Type: news
Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx(TM) System for Chronic Bronchitis
MENLO PARK, Calif., Sept. 16, 2019 -- (Healthcare Sales & Marketing Network) -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device De... Devices Gala Therapeutics, RheOx system, Bronchial Rheoplasty, Chronic Bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 16, 2019 Category: Pharmaceuticals Source Type: news
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx(TM) System for Chronic Bronchitis
First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life
MENLO PARK, Calif., Sept. 4, 2019 -- (Healthcare Sales & Marketing Network) -- Gala Therapeutics, Inc. (Gala) today announced that its RheOx system has... Devices, Regulatory Gala Therapeutics, RheOx, Bronchial Rheoplasty, Chronic Bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 4, 2019 Category: Pharmaceuticals Source Type: news
